Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd completes acquisition of Santarus Inc

Thursday, 2 Jan 2014 04:30pm EST 

Salix Pharmaceuticals Ltd:Says it has completed its previously announced tender offer for all shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc.Says at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.Says as of the expiration of the tender offer, 54,558,962 shares of common stock of Santarus were validly tendered and not validly withdrawn in the tender offer, representing 79.3 percent of the outstanding shares.